186 Re-labeled monoclonal antibody were examined, and its in vivo kinetics was investigated in tumor-bearing Balb/c nu/nu female mice to assess the feasibility of using it in radioimmunotherapy (RIT). A murine IgG 1 , A7, against a 45 kD glycoprotein in human colon cancer was radiolabeled with 186 Re by using a chelating method with a mercaptoacetyltriglycine (MAG3).
Radioimmunotherapy (RIT) using monoclonal antibodies (mAbs) labeled with β emitters has been proven to be a good option for the management of cancer patients. 1, 2) 131 I is the radionuclide that has been most widely used for this purpose. 1, 2) One of the major shortcomings of 131 I is that 131 I radioactivity is rapidly cleared from target tissues after internalization and intracellular metabolism. 3, 4) Another disadvantage of 131 I is high-energy γ emission, 364 keV, that is not ideal for γ detection and exposes patients to unnecessary radiation. With the development of chelating methods, radioimmunoconjugates labeled with radiometals such as 90 Y have been investigated.
5-7)
The chemistry of 90 Y is similar to that of 111 In, and it is well known that 111 In-mAbs are more stable than 131 ImAbs in vivo, and the radioactivity remains inside the cells after intracellular metabolism. 3, 4) However, bifunctional chelates used for 111 In labeling are usually not rigid enough to retain 90 Y, and 90 Y radioactivity released in vivo would accumulate in bone, resulting in an increase of the radiation dose to the bone marrow, a critical organ for RIT. 6, 8) Although the stability of 90 Y-mAbs could be improved by using macrocyclic chelates such as 1,4,7,10-tetraazacyclododecanetetraacetic acid, DOTA, 7) such chelates would stimulate an immune reaction and anti-chelate antibody could be produced in vivo in addition to human anti-mouse antibody. 9) Furthermore, because 90 Y does not have γ emission, imaging is difficult with 90 Y-mAbs and dosimetry should be performed with 111 In-mAb, which may behave differently from 90 Y-mAbs especially as regards the marrow dose. 6, 9) 186 Re appears to be a suitable radionuclide for RIT with an appropriate physical half-life of 3.7 days; this is long enough for a mAb to be localized in tumors and short enough to minimize toxicity to the whole body. Its abundant intermediate-energy β emission (71% of 1.07 MeV and 21% of 0.94 MeV) is comparable to that of 131 I, and its γ emission of 137 keV (9%) is suitable for external detection with γ cameras and produces a lower nonspecific radiation dose than 131 I. 186 Re has similar chemical properties to 99m Tc. Although 99m Tc-mAb is now widely used for radioimmunoscintigraphy (RIS), 10, 11) radiolabeling is performed by a direct labeling method that is not ideal for 186 Re because of the instability of directly labeled 186 Re-mAb. 12) Thus, indirect methods using ligands such as N 2 S 2 , 13) N 2 S 4 14) and N 3 S 15, 16) compounds have been investigated. Among them, a prechelating labeling method using S-benzoyl-mercaptoacetyltriglycine (MAG3), a N 3 S ligand, seems to be a good choice because it can afford high in vivo stability and high specific activity of the labeled mAb. 15) In the present study, we tried to label a mAb A7, a murine IgG 1 , against 45 kD tumor associated glycoprotein expressed on colon cancer cells with 186 Re by using an Sbenzoyl-MAG3 prechelating method. Although the reported response rates to RIT were not high for solid tumors such as colon cancer, 17) small tumors would respond to RIT better than large ones 18) and thus RIT for recurrent masses at the early stage or adjuvant RIT in patients at high risk of recurrence (e.g., Dukes' C patients) would be beneficial. 17, 18) Since RIT would follow the confirmation of recurrence by RIS and/or other modalities, the image quality of RIS should be good enough for postoperative assessment, especially in patients whose anatomical images could not differentiate recurrence from fibrous or granulomatous tissues. The scintigraphic counterpart of 186 Re-mAb is 99m
Tc-mAb, which is superior to 111 In-mAb or 131 I-mAb not only in obtainable image quality, but also in the availability and cost of the radionuclide.
For mAbs labeled with β emitters, we should pay attention to the possibility of autoradiolysis during the storage before the injection. 19, 20) Therefore, we also observed the stability and immunoreactivity of 186 Re-MAG3-A7 for a week, and examined the effect of a radioprotectant or cryopreservation on the radiolysis. Furthermore, the in vivo kinetics of 186 Re-MAG3-A7 was investigated in tumorbearing nude mice, and the feasibility of RIT was tested from a dosimetric viewpoint. These results were compared with those for radioiodine-labeled A7 to see if there would be an advantage in the use of 186 Re-MAG3-A7 over 131 3 (100 mg/ml) and 25 µl of S-benzoyl-MAG3 (1 mg in 1 ml of acetonitrile/H 2 O, 9:1). After evaporation under an N 2 stream, the mixture was further heated for another 15 min. The mixture was reconstituted with 500 µl of water, and incubated with 200 µl of 2, 3, 5, 6-tetrafluorophenol (TFP) (Nacalai Tesque, Kyoto) (100 mg in 1 ml of acetonitrile/H 2 O, 9:1) and 50 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Wako Pure Chemical Industries, Ltd., Osaka) for 30 min after adjustment of the pH to 6 with 1 N H 2 SO 4 . The active ester, 186 Re-MAG3-TFP, was purified on a preconditioned C18 cartridge (Waters, Milford, MA) with 2.5 ml of acetonitrile. The solution was evaporated under an N 2 stream, the residue was dissolved in 500 µl of 0.9% NaCl, and the solution was reacted with 4 mg of A7 in a reaction volume of 2.5 ml for 30 min at room temperature after adjustment of the pH to 9.5 with 0.05 M Na 2 CO 3 . The 186 Re-MAG3-A7 was purified on a PD-10 column (Pharmacia LKB Biotechnology, Uppsala, Sweden) with 0.9% NaCl as an eluant. Re radioactivity was measured by the use of a dose calibrator set for 99m Tc. In this system, 186 Re activity was obtained by multiplying the result by a factor of 2.8. In vitro stability and effect of radioprotectant or cryopreservation 186 Re-MAG3-A7, 2.48-12.7 MBq/mg (2.78-3.55 MBq/ml, Re-MAG3:mAb 0.57-0.76:1), was stored in 0.9% NaCl at 4°C for 7 days, and its stability was assessed by a size-exclusion high-performance liquid chromatography (HPLC) using a TSK3000SW-XL column (Tosoh, Tokyo) with 0.1 M phosphate buffer, pH 7.4, at 1 ml/min. In this system, the retention times of IgG, 186 Re-MAG3 and 186 Re-perrhenate were 8 min, 13.5 min and 13.5 min, respectively. The effect of the presence of 5 mg/ml ascorbic acid 15, 20) and/or preservation at −80°C 19) was examined in the same manner. Stability in human plasma at 37°C, at a concentration of 13.2 µg/ml (168 kBq/ml, 0.1% NaN 3 ), was also assessed for 7 days. There was no evidence of bacterial growth during the 7-day period.
Determination of immunoreactivity
Immunoreactivity of 186 Re-MAG3-A7, 6.70 MBq/mg (6.66 MBq/ml, Re-MAG3:mAb 0.43:1), at infinite antigen excess, was determined after the purification, and was observed during storage with ascorbic acid at 4°C for 8 days, using LS180 human colon carcinoma cells as described by Lindmo et al. 25) Briefly, 100 ng of labeled A7 was incubated with increasing concentrations of cells from 3.75 ×10 5 to 1.2×10 7 in 200 µl for 1 h at room temperature. Non-specific binding was determined by adding 50 µg of cold A7. Triplicate assay was performed for the determination. HPLC assessment was simultaneously performed as described above. In vivo kinetic study and estimated dosimetry Animal studies were performed in compliance with the regulations of our institution. Balb/c nu/nu mice (female, 20 g) were subcutaneously xenografted with 1 ×10 7 LS180 cells in the thigh and used for the experiments 8 days later when tumors weighed 0.2-0.3 g. 186 Re-MAG3-A7 (666 kBq/100 µg, 100 µl) was intravenously injected into the tail vein of mice. The animals were killed at 6 h and 1, 2, 5, 8 days after the injection (n=4-5), and the organs were weighed and counted for radioactivity. The biodistribution of 186 Re-MAG3-A7 was expressed as a percentage of the injected dose per gram of organ (%ID/g). For the dosimetry, we assumed a homogeneous distribution of radioactivity throughout the tissues, ignoring γ-ray absorption. The cumulative radioactivity, µCi * h/g, in various organs after injection of 1 µCi (37 kBq) was calculated by the trapezoidal method using the biodistribution data, from which the radiation dose was estimated by multiplying by a factor of cGy * g/µCi/h for 186 Re of 0.73. 26) In this calculation, the contribution of radiation after 8 days postinjection was omitted. The estimation of whole-body dose was performed as described by Gerretsen et al. 27) To see if there would be an advantage in the use of 186 Re-MAG3-A7 over a radioiodine-labeled A7 in terms of in vivo kinetics, the biodistribution of 125 I-A7 (54.2 MBq/mg, labeled by chloramine-T method) in the same animal model (n=4) was compared with that of 186 Re-MAG3-A7. The dosimetry of 131 I-A7 was done by using the biodistribution data of 125 I-A7 with a factor of cGy * g/ µCi/h for 131 I of 0.40.
28)
Statistical analysis Statistical analysis was performed by use of the unpaired t test to compare the results. In the analysis, the level of significance was set at 5%.
RESULTS
Labeling efficiency of A7 and in vitro assessment of 186 Re-MAG3-A7 The incorporation of 186 Re into S-benzoyl-MAG3 was 87.2%, as assessed by TLC. The efficiency of 186 Re-MAG3-TFP production was 51.4-59.0%, and 56.5-59.5% of 186 Re-MAG3-TFP could be conjugated to A7 mAb. The recovery of radioactivity was 18.9-25.0%.
In 0.9% NaCl at 4°C, the radioactivity dissociated progressively from 186 Re-MAG3-A7, 12.7 MBq/mg (3.55 MBq/ml, Re-MAG3:mAb 0.76:1), as a small molecular weight moiety appearing at 13.5 min on HPLC analysis. During 7-day storage, 42.1% of 186 Re radioactivity was dissociated from the mAb (Fig. 1) . The presence of 5 mg/ ml ascorbic acid could prevent the radiolysis, and 90.3% of the radioactivity remained in the mAb on day 7. The effect of storage at −80°C with or without ascorbic acid was similar. Radiolysis of 186 Re-MAG3-A7 labeled at lower specific activity, 2.48 MBq/mg (2.78 MBq/ml, Re-MAG3:mAb 0.57:1), was negligible even at 4°C without ascorbic acid, as shown in Fig. 2 . In human plasma at a concentration of 13.2 µg/0.17 MBq/ml at 37°C, 13.3% of the 186 Re radioactivity dissociated as a small moiety during 7 days (Fig. 1) .
Immunoreactivity of 186 Re-MAG3-A7 was well preserved, being 68.2% at infinite antigen excess immediately after the PD-10 purification. This was comparable to that of 125 I-A7, 57.8%, and that of 111
In-A7, 62.9%, labeled by the cyclic diethylenetriaminepentaacetic acid, DTPA, method using the same batch of A7 at a 2:1 molar ratio of DTPA:mAb, conditions which would not affect the immunoreactivity of the mAb. The protective effect of ascorbic acid was monitored for 8 days at the specific activity of 6.70 MBq/mg (6.66 MBq/ml, Re-MAG3:mAb 0.43:1). As shown in Fig. 3 , the rate of radiolysis of this preparation was comparable to that of the preparation of 12.7 MBq/mg (3.55 MBq/ml, Re-MAG3:mAb 0.86:1) (Fig. 1) . The reduction of immunoreactivity almost paralleled the dissociation of 186 Re radioactivity from the mAb.
Biodistribution of
186 Re-MAG3-A7 and calculation of radiation dose The results of the biodistribution study in tumor-bearing mice are summarized in Table I and Fig. 4 . Tumor uptake of 186 Re-MAG3-A7 was considerable, amounting to 15.65%ID/g at 6 h after the injection, and peaked on day 1 at 31.00%ID/g. The distribution in normal tissues was most prominent at 6 h and rapidly cleared with time. Although radioactivity was gradually washed , stored at 4°C without ascorbic acid;
, at 4°C with 5 mg/ml ascorbic acid; , at −80°C; , at −80°C with 5 mg/ml ascorbic acid; , in plasma at 37°C. , stored at 4°C without ascorbic acid;
, at 4°C with 5 mg/ml ascorbic acid; , at −80°C without ascorbic acid. , radioactivity bound to protein; , immunoreactivity at infinite antigen excess relative to that observed immediately after the purification. Fig. 4 . Tumor-to-nontumor uptake ratios of 186 Re-MAG3-A7 in colon cancer xenografted mice. , 6 h; , 1 day; , 2 days; , 5 days; , 8 days.
out from the tumor to 5.05%ID/g on day 8, the clearance rate was slower than those of normal tissues, so the tumorto-nontumor uptake ratios increased with time (Fig. 4) . Dosimetry calculation was performed by the trapezoid integration method using the biodistribution data (Table  II) . The calculation was performed up to 8 days, and the later radiation contribution was neglected. After day 8, the doses to normal tissues were negligible and the dose to the tumor would have little effect (Fig. 5) . The ratios of tumor dose to blood and liver doses were 2.23 and 7.32, respectively. For other tissues except for lung, the ratios were greater than 10. Tumor dose was greater than the whole-body dose by a factor of 12.31.
These results were compared with the biodistribution of 125 I-A7 and estimated dosimetry for 131 I-A7 (Tables III and  IV) . Blood clearance of 186 Re-MAG3-A7 was significantly faster than that of 125 I-A7 and the distribution to other normal tissues tended to be less with 186 Re-MAG3-A7, except for the initial hepatic uptake. Tumor uptake of 186 Re-MAG3-A7 was greater until 2 days after the injec- Re-MAG3-A7 in tissues expressed after taking into account physical decay. , blood; , liver; , spleen; , kidney; , bone; , muscle; , intestine; , lung; ×, brain; , heart; , tumor. Re-MAG3-A7 was improved by a factor of 1.67 as compared with 131 I-A7.
DISCUSSION
A major drawback to the usage of 186 Re as a radiolabel of mAb is its low specific activity, because of carrier contamination when 186 Re is produced via the 185 Re(n, γ) reaction. 29) To obtain suitable radioimmunoconjugates of high specific activity for RIT, several 186 Re-MAG3 groups should be coupled to a single mAb molecule. 15, 29, 30) We could label A7 mAb with 186 Re-MAG3 without destroying its immunoreactivity. However, the specific activity of 186 Re-MAG3-A7 was only 12.7 MBq/mg (344 µCi/mg) at best, with a coupling ratio of Re-MAG3:mAb of 0.76:1. In the published results by other investigators, 186 Re-mAb of higher specific activity could be obtained by the conjugation of up to 20 Re-MAG3 groups per mAb, though the immunoreactivity deteriorated with Re-MAG3:mAb higher than 12. 30) In the present study, 186 Re incorporation into MAG3 was performed at Re:MAG3 and Re:Sn 2+ molar ratios of approximately 1 and 6, respectively. Although the incorporation rate, 87.2%, was close to the results of Visser et al., >90%, 15) it appeared that, to obtain a mAb of high specific activity, the Re:MAG3 and Re:Sn 2+ molar ratios should have been increased, as their reaction conditions were Re:MAG3 1:2.3 and Re:Sn 2+ 1:8, and that the reaction volume for the conjugation of mAb should have been reduced or the 186 Re-MAG3:mAb ratio should have been increased. Under such labeling conditions, 186 Re-MAG3-A7 of high specific activity should be obtained.
Although high specific activity would be essential for clinical RIT, difficulties would arise if the labeling of mAb were performed at an extreme molar ratio of Re-MAG3:mAb. 30, 31) It has been reported that coupling of too many Re-MAG3 groups results in an alteration of in vivo distribution and a reduction of immunoreactivity because of the change in the net charge of the mAb and steric hindrance at the mAb binding site. A further drawback to mAbs of high specific activity would be an increase in the susceptibility to autoradiolysis. 19, 20) We observed timedependent dissociation of 186 Re radioactivity during storage even at 12.7 MBq (344 µCi)/mg, 3.55 MBq/ml. Although labeling at lower specific activity would reduce the risk of radiolysis, as shown in Fig. 2 , such low spe- cific activity would not be ideal for clinical RIT because of the need to inject a large amount of mAb to provide sufficient radioactivity. In clinical RIT, 120 mCi/m 2 of 186 Re-mAb could be injected as a maximum tolerated dose in heavily pretreated patients. 32) In this case, 180-259 mCi of 186 Re-NR-LU-10 was injected with 30 ml of 0.9% NaCl at the concentration of 222-318 MBq (6.0-8.6 mCi)/ml, 45-260 mCi/33-47 mg. 32) At this dose level, measures to prevent autoradiolysis of labeled mAbs are essential. 15) Addition of 5 mg/ml ascorbic acid as a radioprotectant to the mAb solution could effectively prevent radiolysis of the mAb. Storage at −80°C, cryopreservation, was equally effective. Since the reduction of immunoreactivity is not completely accounted for by the breakdown products, 20) immunoreactivity should be monitored as well in the assessment of radiolysis. As shown in Fig. 3 , 5 mg/ml ascorbic acid could protect A7 from loss of immunoreactivity, as well as breakdown. Because the susceptibility to radiation may vary among mAbs, assessment of individual mAbs may be necessary. Although long-term storage of 186 Re-mAb would not be needed in the clinical setting, radiolysis can occur in a very short period. It was reported that 6% of radioactivity was lost from 186 Re-MAG3 labeled anti-squamous cell carcinoma mAb within 20 min.
15) Therefore, we have to recognize that, without protection of the mAb from possible radiolysis and loss of immunoreactivity, the results of RIT could be affected even by brief storage.
In human plasma, 86.7% of 186 Re radioactivity remained on A7 mAb after a 7-day incubation. Similar stability in human plasma was observed with 186 Re-MAG3-ZCE025, an anti-CEA mAb: 92.8% and 87.5% of 186 Re remained bound on day 7 and day 12, respectively (data not shown). In contrast, only 58-64% of 186 Re was found on a directly labeled 186 Re-Mu-9 in human serum on day 7, or 85% of 188 Re-Mu-9 on day 2. 12) These findings indicated that mAb labeled with a MAG3 ligand would be more stable than directly labeled mAbs in terms of dissociation of radioactivity, although comparison is difficult since Griffiths et al. did not give the concentration of mAb in their test solution. Furthermore, although they mentioned the in vivo stability, showing that all of the radioactivity was bound to Mu-9 at 24 h postinjection in serum from mice injected with 188 Re-Mu-9, 12) this finding does not confirm the stability of their Re-mAbs because the mechanism of instability of directly labeled Re-mAbs would be reoxidation of conjugated Re to produce perrhenate that is rapidly cleared from the circulation. The precise form of the breakdown products found in the present study was not clear. They were eluted at 13.5 min on the size exclusion HPLC column used in this study, but both 186 Re-MAG3 and 186 Re-perrhenate would emerge at the same retention time. Further analyses by TLC or reverse-phase HPLC would cast light on this issue.
Tumor uptake of 186 Re-MAG3-A7 was very high, peaking on day 1 with slower washout than from normal tissues, so that the tumor-to-nontumor ratios increased with time. Tumor accumulation was greater than that of 125 I-A7. 186 Re radioactivity was cleared from tumors faster than 125 I after the peak uptake. However, this would not be a serious problem for RIT because of the shorter physical half life, 3.7 days, than that of 131 I, 8.0 days. Beaumier et al. reported that LD 50/30 was 600 µCi, corresponding to 880 cGy of whole-body dose, in an experimental RIT study with 186 Re-NR-LU-10 in a mouse model bearing small cell lung cancer. 33) In our model, a value of 726 cGy of whole-body dose was estimated, suggesting that the toxicity of 186 Re-MAG3-A7 is comparable to that of 186 Re-NR-LU-10. The tumor-to-whole body radiation dose in the present study was 12.34, which is 5-fold larger than their result. In their study, 19% remission was obtained with a total of 500-600 µCi injection (2012-2671 cGy to the tumor). Gerretsen et al. reported another experimental RIT in a head and neck squamous cell cancer model using 186 Re-MAG3-E48, obtaining 33% remission by 400-600 µCi injection, with 3432 cGy to the tumor at 600 µCi. 27) In our model, we estimated a tumor dose of 8916 cGy with 600 µCi of 186 Re-MAG3-A7. Although radiation sensitivity might vary among these cell types and we could not conduct an experimental RIT with 186 Re-MAG3-A7 because of the limited amount of 186 Re permitted to be used under the regulations of our institution, the dosimetry results in the present study indicate the feasibility of RIT with 186 Re-MAG3-A7. Our previous experimental RIT study with 9.25 MBq (250 µCi) of 131 I-A7 in the same animal model as used in this study showed a significant suppression of tumor growth. 34) This dosage could produce a tumor burden of 2150 cGy, which is far less than the expected dose with 186 Re-MAG3-A7 mentioned above. Because of the higher therapeutic ratios of 186 Re-MAG3-A7, 186 Re-MAG3-A7 would be more favorable than 131 I-A7 in terms of toxicity as well. Therefore, it is clear that a greater tumor radiation dose could be delivered by 186 Re-MAG3-A7 with the same toxicity to normal tissues as in the case of 131 I-A7, and better results of RIT should be achieved with 186 Re-MAG3-A7. In conclusion, it is crucial to protect 186 Re-mAb against autoradiolysis. The in vivo characteristics of 186 Re-MAG3-A7 were better than those of conventional 131 I-A7 in terms of both tumor dosimetry and normal tissue irradiation doses, indicating that 186 Re-MAG3-A7 should be superior to 131 I-A7 as a candidate for RIT of colorectal cancer. Although some improvement in the labeling process would be needed to get 186 Re-MAG3-A7 of higher specific activity, RIT with 186 Re-MAG3-A7 seems to be a promising modality.
